SARS-CoV-2 Spike RBD LlaMABodyTM Bivalent VHH HuIgG2 Fusion Antibody, R&D Systems™

Spike RBD

Blockade of Receptor-ligand Interaction 50 ug/mL

Monoclonal

Purified

RUO

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS.

Human embryonic kidney cell HEK293-derived SARS-CoV-2 Spike RBD as immunogen for bivalent Llama VHH-Human IgG2 Fusion Antibody., Arg319-Phe541, Accession # YP_009724390.1

Protein A or G purified from cell culture supernatant

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

L009.1.32H

Blocking Assay

Unconjugated

Llama

SARS-CoV-2

YP_009724390.1

Primary

Reconstitute at 0.5 mg/mL in sterile PBS.